Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
about
Signalling to eIF4E in cancerDesign of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisationSynthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.Targeting the eIF4F translation initiation complex: a critical nexus for cancer developmentDistinct features of cap binding by eIF4E1b proteinsTransforming Growth Factor-β1 Induced Epithelial Mesenchymal Transition is blocked by a chemical antagonist of translation factor eIF4EPotential therapeutic applications of RNA cap analogs.Analysis of mononucleotides by tandem mass spectrometry: investigation of fragmentation pathways for phosphate- and ribose-modified nucleotide analogues.Targeting translation: eIF4E as an emerging anticancer drug target.Translational control of the fibroblast-extracellular matrix association: An application to pulmonary fibrosis.Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics.Targeting eukaryotic protein translation in mesotheliomamRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translationDesign, Synthesis, and Characterization of Sulfamide and Sulfamate Nucleotidomimetic Inhibitors of hHint1.Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.Switch-on fluorescent/FRET probes to study human histidine triad nucleotide binding protein 1 (hHint1), a novel target for opioid tolerance and neuropathic pain.Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation.
P2860
Q26777735-F0371B49-91F9-4C8E-BB2E-38B2711B0111Q27727984-348A6635-8DC9-4DC6-9B51-BC99A4B581ACQ34249684-AA558694-F873-4EC0-AB8C-D43A5C431B25Q34988282-E4387483-5CF8-4853-A64A-6572B23E3E55Q35013573-EE715752-C326-4741-842A-CDC02B80C756Q36382304-7A0EFDAE-1D16-41BA-A506-53EE522E1F21Q38116576-EFA98A36-40FC-4915-A892-03C85745BCF2Q38615354-F988710B-ED5F-4AB9-A476-13576D17FF24Q38699320-52CB8210-86DF-415C-9348-6B4B65C8AE56Q38715693-1085FE63-B322-4C17-B497-93209AE697EBQ39006692-63E378AB-937B-424F-B5BA-CB3E5725CCA6Q39068205-F7578AF4-DD1F-4B73-8D25-2F3FCC81A9DAQ39438189-D8208400-C45E-4CD6-A18C-BAB0F5D03EEAQ41630115-B22AC7B8-EFAF-4750-A9F8-573CE7ACB1FDQ41907046-FDC6E168-E668-4D8C-BDB8-4409A94DF722Q42557873-9BBBF9DB-59E0-4D48-BBFC-F913389D7559Q47362986-1E0CBCC3-B447-43E8-BDC4-CF2E7C7AF151Q52684406-9EA049C6-7D18-4D61-B6E6-17312649992E
P2860
Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Treatment of breast and lung c ...... eIF4E proteasomal degradation.
@en
Treatment of breast and lung c ...... phosphoramidate pronucleotide
@nl
type
label
Treatment of breast and lung c ...... eIF4E proteasomal degradation.
@en
Treatment of breast and lung c ...... phosphoramidate pronucleotide
@nl
prefLabel
Treatment of breast and lung c ...... eIF4E proteasomal degradation.
@en
Treatment of breast and lung c ...... phosphoramidate pronucleotide
@nl
P2093
P2860
P356
P1476
Treatment of breast and lung c ...... eIF4E proteasomal degradation
@en
P2093
Blake Jacobson
Carston R Wagner
Joel McCauley
Robert Kratzke
P2860
P304
P356
10.1021/MP300699D
P407
P577
2013-02-01T00:00:00Z